Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats

Journal of Pharmacy and Pharmacology

Volumn 66, Issue 7, 2014, Pages 975-987

  Tahara, Atsuo ^a   Kurosaki, Eiji ^a   Yokono, Masanori ^a   Yamajuku, Daisuke ^a   Kihara, Rumi ^a   Hayashizaki, Yuka ^a   Takasu, Toshiyuki ^a   Imamura, Masakazu ^a   Li, Qun ^b   Tomiyama, Hiroshi ^c   Kobayashi, Yoshinori ^c   Noda, Atsushi ^c   Sasamata, Masao ^a   Shibasaki, Masayuki ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b Astellas Pharma Global Development   (Netherlands)

^c Kotobuki Pharmaceutical Co Ltd   (Japan)

Author keywords

diabetes; hyperglycaemia; ipragliflozin; SGLT2; urinary glucose excretion

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; INSULIN; INTERLEUKIN 6; IPRAGLIFLOZIN; MONOCYTE CHEMOTACTIC PROTEIN 1; SODIUM GLUCOSE COTRANSPORTER 2; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TUMOR NECROSIS FACTOR ALPHA; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLUCOSIDE; STREPTOZOCIN; THIOPHENE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMINURIA; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG SCREENING; FATTY LIVER; GLOMERULUS FILTRATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSURIA; HEMODYNAMIC PARAMETERS; HEPATITIS; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; LIVER INJURY; MALE; MORNING DOSAGE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; PROTEIN FUNCTION; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; GLOMERULUS FILTRATION RATE; GLUCOSE INTOLERANCE; HYPERLIPIDEMIAS; INFLAMMATION; KIDNEY; LIVER; METABOLISM; SPRAGUE DAWLEY RAT;

ALBUMINURIA; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; FATTY LIVER; GLOMERULAR FILTRATION RATE; GLUCOSE INTOLERANCE; GLUCOSIDES; HYPERGLYCEMIA; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; INFLAMMATION; KIDNEY; LIVER; MALE; OXIDATIVE STRESS; RATS, SPRAGUE-DAWLEY; SODIUM-GLUCOSE TRANSPORTER 2; STREPTOZOCIN; THIOPHENES;

EID: 84902536157     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12223     Document Type: Article

References (39)

1. Wright EM, Turk E,. The sodium/glucose cotransport family SLC5. Pflugers Arch 2004; 447: 510-518.
2. Pajor AM, Wright EM,. Cloning and functional expression of a mammalian Na+/nucleoside cotransporter. A member of the SGLT family. J Biol Chem 1992; 267: 3557-3560.
3. Turk E, et al. Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter. Nature 1991; 350: 354-356.
4. Wells RG, et al. Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Physiol 1992; 263: F459-F465.
5. van den Heuvel LP, et al. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet 2002; 111: 544-547.
6. Blondel O, et al. Insulin resistance in rats with non-insulin-dependent diabetes induced by neonatal (5 days) streptozotocin: evidence for reversal following phlorizin treatment. Metabolism 1990; 39: 787-793.
7. Rossetti L, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987; 79: 1510-1515.
8. Kahn BB, et al. Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest 1991; 87: 561-570.
9. Ehrenkranz JR, et al. Phlorizin: a review. Diabetes Metab Res Rev 2005; 21: 31-38.
10. Chao EC, Henry RR,. SGLT2 inhibition-a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010; 9: 551-559.
11. Tahara A, et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn-Schmiedeberg's. Arch Pharmacol 2012; 385: 423-436.
12. Tahara A, et al. Effects of antidiabetic drugs in high-fat diet and streptozotocin-nicotinamide-induced type 2 diabetic mice. Eur J Pharmacol 2011; 655: 108-116.
13. Ji G, et al. Anti-inflammatory effect of genistein on non-alcoholic steatohepatitis rats induced by high fat diet and its potential mechanisms. Int Immunopharmacol 2011; 11: 762-768.
14. Nakhaee A, et al. Attenuation of oxidative stress in streptozotocin- induced diabetic rats by eucalyptus globulus. Indian J Clin Biochem 2009; 24: 419-425.
15. Atkinson MA, Eisenbarth GS,. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001; 358: 221-229.
16. Borchers AT, et al. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 2010; 9: A277-A287.
17. Daneman D,. Type 1 diabetes. Lancet 2006; 367: 847-858.
18. Cryer PE,. Diverse causes of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 2004; 350: 2272-2279.
19. Nathan DM, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
20. Bluestone JA, et al. Pathogenesis and clinical interventions in type 1 diabetes. Nature 2010; 464: 1293-1300.
21. Cryer PE,. Preventing hypoglycaemia: what is the appropriate glucose alert value? Diabetologia 2009; 52: 35-37.
22. Leahy JL,. Beta-cell dysfunction with chronic hyperglycemia: 'overworked beta-cell' hypothesis. Diabetes Rev 1996; 4: 298-319.
23. Delaney MF, et al. Diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Endocrinol Metab Clin North Am 2000; 29: 683-705.
24. Hebden RA, et al. The influence of streptozotocin-induced diabetes mellitus on fluid and electrolyte handling in rats. Clin Sci 1986; 70: 111-117.
25. Wu KK, Huan Y,. Streptozotocin-induced diabetic models in mice and rats. Curr Protoc Pharmacol 2008; 40: 1-14.
26. Havel PJ, et al. Effects of streptozotocin-induced diabetes and insulin treatment on the hypothalamic melanocortin system and muscle uncoupling protein 3 expression in rats. Diabetes 2000; 49: 244-252.
27. English P, Williams G,. Hyperglycaemic crises and lactic acidosis in diabetes mellitus. Postgrad Med J 2004; 80: 253-261.
28. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
29. Yotsumoto T, et al. Effects of specific antagonists of angiotensin II receptors and captopril on diabetic nephropathy in mice. Jpn J Pharmacol 1997; 75: 59-64.
30. O'Donnell MP, et al. Glomerular hemodynamic and structural alterations in experimental diabetes mellitus. FASEB J 1988; 2: 2339-2347.
31. Seyer-Hansen K, et al. Renal hypertrophy in experimental diabetes. A morphometric study. Diabetologia 1980; 18: 501-505.
32. Glaser NS, et al. Detecting and treating hyperlipidemia in children with type 1 diabetes mellitus: are standard guidelines applicable to this special population? Pediatr Diabetes 2011; 12: 442-459.
33. Goldberg IJ,. Clinical review 124: diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab 2001; 86: 965-971.
34. Regnell SE, Lernmark A,. Hepatic steatosis in type 1 diabetes. Rev Diabet Stud 2011; 8: 454-467.
35. Targher G, et al. Increased prevalence of chronic kidney disease in patients with Type 1 diabetes and non-alcoholic fatty liver. Diabet Med 2012; 29: 220-226.
36. Baskol G, et al. Oxidative stress and antioxidant defenses in serum of patients with non-alcoholic steatohepatitis. Clin Biochem 2007; 40: 776-780.
37. Tripathy D, et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003; 52: 2882-2887.
38. Dominguez C, et al. Oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents. Diabetes Care 1998; 21: 1736-1742.
39. Snell-Bergeon JK, et al. Inflammatory markers are increased in youth with type 1 diabetes: the SEARCH Case-Control study. J Clin Endocrinol Metab 2010; 95: 2868-2876.